SPYRE THERAPEUTICS, INC. Deferred Tax Liabilities, Unrealized Gains on Trading Securities
SPYRE THERAPEUTICS, INC. (SYRE) had Deferred Tax Liabilities, Unrealized Gains on Trading Securities of $183.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities · last filed 2026-02-19
- 2025-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $183.00K.
- 2024-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $92.00K.
- 2023-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $0.00.
- 2022-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $0.00.
| Period end | Deferred Tax Liabilities, Unrealized Gains on Trading Securities |
|---|---|
| 2025-12-31 | $183.00K 10-K · filed 2026-02-19 |
| 2024-12-31 | $92.00K 10-K · filed 2026-02-19 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |